(Circulation. 1999;99:1084-1090.)
© 1999 American Heart Association, Inc.
Basic Science Reports |
Tranilast Suppresses Vascular Chymase Expression and Neointima Formation in Balloon-Injured Dog Carotid Artery
From the Department of Pharmacology, Osaka Medical College (N. Shiota, S.T., I.M, H.S., M.M.), Takatsuki, Japan; the Department of Pharmacology, Shimane Medical University (H.O.), Izumo, Japan; and Second Research Laboratories, Kissei Pharmaceutical Co, Ltd (N. Shibata), Nagano, Japan.
Correspondence to Naotaka Shiota, MD, PhD, Department of Pharmacology, Osaka Medical College, 2-7 Daigakumachi, Takatsuki, Osaka 569, Japan.
Background—Activation of vascular chymase plays a major role in myointimal hypertrophy after vascular injury by augmenting the production of angiotensin (ANG) II. Because chymase is synthesized mainly in mast cells, we assumed that the chymase-dependent ANG II formation could be downregulated by tranilast, a mast cell–stabilizing antiallergic agent. We have assessed inhibitory effects of tranilast on neointima formation after balloon injury in the carotid artery of dogs, which share a similar ANG II–forming chymase with humans, and further explored the pathophysiological significance of vascular chymase.
Methods and Results—Either tranilast (50 mg/kg BID) or vehicle was orally administered to beagles for 2 weeks before and 4 weeks after balloon injury. Four weeks after the injury, remarkable neointima was formed in the carotid arteries of vehicle-treated dogs. Chymase mRNA levels and chymaselike activity of vehicle-treated injured arteries were increased 10.2- and 4.8-fold, respectively, those of uninjured arteries. Angiotensin-converting enzyme (ACE) activity was slightly increased in the injured arteries, whereas ACE mRNA levels were not. Tranilast treatment completely prevented the increase in chymaselike activity, reduced the chymase mRNA levels by 43%, and decreased the carotid intima/media ratio by 63%. In vehicle-treated injured arteries, mast cell count in the adventitia showed a great increase, which was completely prevented by the tranilast treatment. Vascular ACE activity and mRNA levels were unaffected by tranilast.
Conclusions—Tranilast suppressed chymase gene expression, which was specifically activated in the injured arteries, and prevented neointima formation. Suppression of the chymase-dependent ANG II–forming pathway may contribute to the beneficial effects of tranilast.
Key Words: angiotensin • leukocytes • restenosis • angiogenesis • polymerase chain reaction
This article has been cited by other articles:
 |
|
 |
|
  W. W. Raymond, S. Su, A. Makarova, T. M. Wilson, M. C. Carter, D. D. Metcalfe, and G. H. Caughey {alpha}2-Macroglobulin Capture Allows Detection of Mast Cell Chymase in Serum and Creates a Reservoir of Angiotensin II-Generating Activity J. Immunol., May 1, 2009; 182(9): 5770 - 5777. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nachtigal, A. Ghaffar, and E. P. Mayer Galectin-3 Gene Inactivation Reduces Atherosclerotic Lesions and Adventitial Inflammation in ApoE-Deficient Mice Am. J. Pathol., January 1, 2008; 172(1): 247 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. N. Lavrentyev, A. M. Estes, and K. U. Malik Mechanism of High Glucose Induced Angiotensin II Production in Rat Vascular Smooth Muscle Cells Circ. Res., August 31, 2007; 101(5): 455 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Jin, H. Ueda, S. Takai, Y. Okamoto, M. Muramatsu, M. Sakaguchi, N. Shibahara, Y. Katsuoka, and M. Miyazaki Effect of Chymase Inhibition on the Arteriovenous Fistula Stenosis in Dogs J. Am. Soc. Nephrol., April 1, 2005; 16(4): 1024 - 1034. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A Doggrell and J. C Wanstall Vascular chymase: pathophysiological role and therapeutic potential of inhibition Cardiovasc Res, March 1, 2004; 61(4): 653 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. McPherson, Z. Luo, R. A. Brown, L. S. LeBard, C. C. Corless, R. C. Speth, and S. P. Bagby Chymase-like Angiotensin II-Generating Activity in End-Stage Human Autosomal Dominant Polycystic Kidney Disease J. Am. Soc. Nephrol., February 1, 2004; 15(2): 493 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Matsumoto, A. Wada, T. Tsutamoto, M. Ohnishi, T. Isono, and M. Kinoshita Chymase Inhibition Prevents Cardiac Fibrosis and Improves Diastolic Dysfunction in the Progression of Heart Failure Circulation, May 27, 2003; 107(20): 2555 - 2558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Takai, H. Sakonjo, K. Fukuda, D. Jin, M. Sakaguchi, K. Kamoshita, K. Ishida, Y. Sukenaga, and M. Miyazaki A Novel Chymase Inhibitor, 2-(5-Formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-[{3,4-dioxo-1-phenyl-7-(2-pyridyloxy)}-2-heptyl]acetamide (NK3201), Suppressed Intimal Hyperplasia after Balloon Injury J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 841 - 844. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Spiecker, I. Lorenz, N. Marx, and H. Darius Tranilast Inhibits Cytokine-Induced Nuclear Factor kappa B Activation in Vascular Endothelial Cells Mol. Pharmacol., October 1, 2002; 62(4): 856 - 863. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H Chester Mast cells feel the strain Cardiovasc Res, July 1, 2002; 55(1): 13 - 15. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tokuyama, K. Hayashi, H. Matsuda, E. Kubota, M. Honda, K. Okubo, I. Takamatsu, S. Tatematsu, Y. Ozawa, S. Wakino, et al. Differential Regulation of Elevated Renal Angiotensin II in Chronic Renal Ischemia Hypertension, July 1, 2002; 40(1): 34 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Ward, A. Agrotis, P. Kanellakis, J. Hall, G. Jennings, and A. Bobik Tranilast Prevents Activation of Transforming Growth Factor-{beta} System, Leukocyte Accumulation, and Neointimal Growth in Porcine Coronary Arteries After Stenting Arterioscler Thromb Vasc Biol, June 1, 2002; 22(6): 940 - 948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hara, K. Ono, M.-W. Hwang, A. Iwasaki, M. Okada, K. Nakatani, S. Sasayama, and A. Matsumori Evidence for a Role of Mast Cells in the Evolution to Congestive Heart Failure J. Exp. Med., February 4, 2002; 195(3): 375 - 381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Yau, D. P. Wilson, J. P. Werner, and P. Zahradka Bradykinin receptor antagonists attenuate neointimal proliferation postangioplasty Am J Physiol Heart Circ Physiol, October 1, 2001; 281(4): H1648 - H1656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Izawa, J.-i. Suzuki, W. Takahashi, J. Amano, and M. Isobe Tranilast Inhibits Cardiac Allograft Vasculopathy in Association With p21Waf1/Cip1 Expression on Neointimal Cells in Murine Cardiac Transplantation Model Arterioscler Thromb Vasc Biol, July 1, 2001; 21(7): 1172 - 1178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ju, R. Gros, X. You, S. Tsang, M. Husain, and M. Rabinovitch Conditional and targeted overexpression of vascular chymase causes hypertension in transgenic mice PNAS, June 19, 2001; 98(13): 7469 - 7474. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nishimoto, S. Takai, Y. Sawada, A. Yuda, K. Kondo, M. Yamada, D. Jin, M. Sakaguchi, K. Asada, S. Sasaki, et al. Chymase-dependent angiotensin II formation in the saphenous vein versus the internal thoracic artery J. Thorac. Cardiovasc. Surg., April 1, 2001; 121(4): 729 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Touyz and E. L. Schiffrin Signal Transduction Mechanisms Mediating the Physiological and Pathophysiological Actions of Angiotensin II in Vascular Smooth Muscle Cells Pharmacol. Rev., December 1, 2000; 52(4): 639 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ishiwata, S. Verheye, K. A. Robinson, M. Y. Salame, H. de Leon, S. B. King III, and N. A. F. Chronos Inhibition of neointima formation by tranilast in pig coronary arteries after balloon angioplasty and stent implantation J. Am. Coll. Cardiol., April 1, 2000; 35(5): 1331 - 1337. [Abstract] [Full Text] [PDF]
|
|